PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Clinical predictors for the prognosis of myasthenia gravis.

Abstract Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis.
PMID
Related Publications

Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors.

β2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality.

Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.

Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.

Authors

Mayor MeshTerms
Keywords

Myasthenia gravis

Ocular

Prognosis

Relapse

Journal Title bmc neurology
Publication Year Start




PMID- 28420327
OWN - NLM
STAT- MEDLINE
DA  - 20170419
DCOM- 20170516
LR  - 20170516
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 19
TI  - Clinical predictors for the prognosis of myasthenia gravis.
PG  - 77
LID - 10.1186/s12883-017-0857-7 [doi]
AB  - BACKGROUND: Clinical predictors for myasthenia gravis relapse and ocular
      myasthenia gravis secondary generalization during the first two years after
      disease onset remain incompletely identified. This study attempts to investigate 
      the clinical predictors for the prognosis of Myasthenia Gravis. METHODS: Eighty
      three patients with myasthenia gravis were concluded in this study. Baseline
      characteristics were analyzed as predictors. RESULTS: Relapse of myasthenia
      gravis developed in 26 patients (34%). Generalization developed in 34 ocular
      myasthenia gravis patients (85%). Other autoimmune diseases were observed more
      commonly in relapsed myasthenia gravis (P = 0.012). Second generalization group
      contained more late onset patients (P = 0.021). Ocular myasthenia gravis patients
      with thymus hyperplasia progressed more rapidly than those with other thymus
      pathology (P = 0.027). Single onset symptom of ocular myasthenia gravis such as
      ptosis or diplopia predicted early progression than concurrence of ptosis and
      diplopia (P = 0.027). Treatment effect including glucocorticoid, pyridostigmine, 
      thymectomy, IVIG, immunosuppressive drugs did not show significant difference
      between the relapsed and non-relapsed groups. The treatment outcome also showed
      no difference between the single OMG and second generalized groups. CONCLUSIONS: 
      Occurrence of associated autoimmune disease can serve as a potential predictor
      for myasthenia gravis relapse. Either ptosis or diplopia, as well as thymic
      hyperplasia can predict generalization in the first six months.
FAU - Wang, Lili
AU  - Wang L
AD  - Department of Neurology, Beijing Shijitan Hospital, Capital Medical University,
      Beijing, 100038, People's Republic of China. [email protected]
FAU - Zhang, Yun
AU  - Zhang Y
AD  - Department of Neurology, Beijing Shijitan Hospital, Capital Medical University,
      Beijing, 100038, People's Republic of China.
FAU - He, Maolin
AU  - He M
AD  - Department of Neurology, Beijing Shijitan Hospital, Capital Medical University,
      Beijing, 100038, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170419
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myasthenia Gravis/complications/*diagnosis
MH  - Prognosis
MH  - Recurrence
MH  - Risk Factors
PMC - PMC5395963
OTO - NOTNLM
OT  - Myasthenia gravis
OT  - Ocular
OT  - Prognosis
OT  - Relapse
EDAT- 2017/04/20 06:00
MHDA- 2017/05/17 06:00
CRDT- 2017/04/20 06:00
PHST- 2017/01/26 [received]
PHST- 2017/04/12 [accepted]
AID - 10.1186/s12883-017-0857-7 [doi]
AID - 10.1186/s12883-017-0857-7 [pii]
PST - epublish
SO  - BMC Neurol. 2017 Apr 19;17(1):77. doi: 10.1186/s12883-017-0857-7.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>